Blue Shield California will no longer pay for the use of Avastin to treat metastatic breast cancer.
NATIONAL REPORTS- Blue Shield of California will no longer pay for the use of Avastin (bevacizumab) to treat metastatic breast cancer, according to The New York Times.
In a followup statement, Blue Shield said a panel of oncology experts will review each new treatment request individually, and Avastin will be covered if the panel determines it to be medically necessary. The plan will continue to cover Avastin for advanced breast cancer for any covered member currently under treatment with Avastin.
Non-coverage trends are growing, according to Randy Vogenberg, PhD, principal at the Institute for Integrated Healthcare in Sharon, Mass., and executive director of the Biologic Access & Finance program at The Jefferson School of Population Health in Philadelphia.
Once reimbursement changes like this occur, more restrictions can follow in less-obvious areas of medication or medical care, adds Vogenberg.
Blue Shield is said to be the first large insurance company to end payments since FDA's Oncologic Drugs Advisory Committee recommended in June that FDA withdraw its approval of Avastin in combination with paclitaxel chemotherapy for previously untreated (first-line) HER2-negative metastatic breast cancer. The committee's recommendation is not the final decision and Avastin plus paclitaxel is still FDA approved for women with HER2-negative metastatic breast cancer.
The FDA Commissioner will make the final decision on whether Avastin should remain approved for metastatic breast cancer. FDA has not announced when that will happen.
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Merith Basey Advocates for Transparency in PBM Practices | AHIP 2024
June 11th 2024Merith Basey, M.Sc., executive director of Patients for Affordable Drugs, discusses her group's focus on the monopoly pricing of pharmaceutical companies and bills in Congress addressing patent reform and "pay for delay" strategies, in an interview with MHE previewing the presentation she's co-presenting on June 11 at the AHIP 2024 meeting in Las Vegas.
Read More
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More